Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
10 July 2015 |
Main ID: |
EUCTR2006-001834-42-FR |
Date of registration:
|
05/10/2006 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
A Multi-Center, Open label, Repeated Dose Range Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Efficacy of an Anti-IL-1ß Monoclonal Antibody (ACZ885) Given Subcutaneously in Pediatric Subjects with Active Systemic Juvenile Idiopathic Arthritis (SJIA)
|
Scientific title:
|
A Multi-Center, Open label, Repeated Dose Range Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Efficacy of an Anti-IL-1ß Monoclonal Antibody (ACZ885) Given Subcutaneously in Pediatric Subjects with Active Systemic Juvenile Idiopathic Arthritis (SJIA) |
Date of first enrolment:
|
17/04/2007 |
Target sample size:
|
26 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-001834-42 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes
Randomised: no
Open: yes
Single blind: no
Double blind: no
Parallel group: yes
Cross over: no
Other: no
Other trial design description: Parallel groups in stage I
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: no
|
Phase:
|
|
|
Countries of recruitment
|
France
|
Italy
|
United Kingdom
| | | | | |
Contacts
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: - Male and female subjects aged 4 to 20 years at the time of the screening visit, having passed screening examinations. Parents’ or legal guardian’s written informed consent (patient’s informed consent for = 18 years of age) and child’s assent, if appropriate, are required prior to study participation.
- Female subjects of child-bearing potential may participate if they have a negative serum pregnancy test at screening and prior to dosing, and are willing to practice double-barrier contraception during the study (from the date of screening) and for at least 3 months following the last dose.
- Patient meets the diagnostic criteria for SJIA and has active disease defined as active arthritis (using ACR definition of active joint) in at least one joint for the last 6 weeks (does not have to be the same joint) and within 2 weeks of study entry at least one of the following systemic features considered by the treating physician to be due to SJIA: spiking, intermittent fever (body temperature > 38.9°C only for several hours during the day), and CRP > 50 mg/L (normal range < 10 mg/L). - Anakinra naïve or willing to discontinue anakinra under close monitoring (run in phase) until relapse (reappearance of fever and/or CRP increase).
- Able to discontinue second line agent such as disease-modifying and immunosuppressive drugs, not including methotrexate and corticosteroids. - If part of the treatment at screening visit: Stable dose of methotrexate (maximum of 15 mg/m2/week) for at least eight weeks prior to the screening visit, and folic/folinic acid supplementation (according to standard medical practice of the center). Stable dose of no more than one NSAID for at least four weeks prior to the screening visit. Stable dose of oral prednisone (= 0.4 mg/kg/day or = 20 mg/day, whichever is lower) for at least one week prior to the screening visit.
- Body weight of at least 12 kg.
- Negative tuberculin skin test reaction (PPD 5 TU) (< 5 mm induration) at 48 to 72 hours after administration at the screening visit or within 2 months prior to the screening visit, according to national guidelines. Patients who have a positive PPD skin test with a documentation of BCG vaccination, who are at low environmental risk for tuberculosis infection or reactivation, and have a negative chest X-ray can be included A positive PPD sample will be defined using the MMWR 2000 guidance, summarized as criteria for tuberculin positivity by risk group. Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria: - Etanercept in the four weeks prior to the Baseline visit
- Adalimumab in the eight weeks prior to the Baseline visit
- Infliximab in the eight weeks prior to the Baseline visit
- Any other investigational biologics in the eight weeks prior to the Baseline visit
- Leflunomide in the four weeks prior to the Baseline visit. Documentation of a completion of a full cholestyramine elimination procedure after most recent leflunomide use will be required
- Cyclosporine in the four weeks prior to the Baseline visit
- Sulfasalazine or hydroxychloroquine in the eight weeks prior to the Baseline visit
- i.v. immunoglobulin (i.v. Ig) in the eight weeks prior to the Baseline visit
- 6-Merceptopurine, azathioprine, cyclophosphamide, or chlorambucil, in the 24 weeks prior to the Baseline visit
- History of recurrent bacterial, fungal or viral infection.
- Evidence of currently active bacterial, fungal or viral infection.
- Administration of live attenuated vaccine.
- Uncontrolled severe systemic symptoms and/or biologic features of Macrophage Activation Syndrome (hemorrhages, central nervous system dysfunction, hepatomegaly, serum fibrinogen level < 2.5 g/L, cytopenia, hypertriglyceridemia, decreased platelet count, increased aspartate transaminase, hyperferritinemia).
- Familial and social conditions rendering regular medical assessment not possible.
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Systemic Juvenile Idiopathic Arthritis (SJIA) MedDRA version: 8.1
Level: PT
Classification code 10059177
Term: Juvenile arthritis
|
Intervention(s)
|
Product Name: ACZ885 Product Code: ACZ885 Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: ACZ885 Drug Substance Current Sponsor code: ACZ885 Other descriptive name: ACZ885 Drug Substance Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-
|
Primary Outcome(s)
|
Primary end point(s): See E.2.1
|
Secondary Objective: • To assess the proportion of patients with inactive disease at each dose level. • To investigate the possibility of corticosteroid tapering. • To establish a biomarker and pharmacogenomic characterization of these patients at baseline and to evaluate the treatment response to ACZ885.
|
Main Objective: • To evaluate the safety, tolerability and immunogenicity of sc administration of ACZ885 in pediatric subjects with active Systemic Juvenile Idiopathic Arthritis (SJIA).
• To assess the initial efficacy profile (% responders to treatment and time to relapse) of sc dosing of ACZ885 in pediatric subjects with active SJIA according to the modified American College of Rheumatology (ACR) pediatric 30 definitions and the ability of ACZ885 to control the systemic manifestations of SJIA such as fever and rash.
• To assess the PK of ACZ885 administered sc in children.
• To assess PK and PD relationships in order to derive a dose and dosing regimen for Phase III (dose and dosing frequency required for relief of signs and symptoms and response according to at least ACR 30 definition).
|
Secondary ID(s)
|
not available
|
CACZ885A2203
|
Source(s) of Monetary Support
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|